Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Skyrizi entities : Abbvie inc. save search
AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints
Published: 2023-10-15 (Crawled : 16:20) - prnewswire.com
ABBV | $163.45 1.1% 1.3M
|
Health Technology
| Email alert
Add to watchlist
skyrizi disease study
AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease
Published: 2023-09-12 (Crawled : 14:30) - biospace.com/
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: 0.31%
H: 0.07%
C: -0.15%
skyrizi disease study
SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study
Published: 2023-07-26 (Crawled : 12:00) - prnewswire.com
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
skyrizi psoriasis study
Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
Published: 2023-03-23 (Crawled : 15:00) - biospace.com/
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: 0.28%
H: 1.56%
C: 0.78%
skyrizi risankizumab study ulcerative colitis
AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque Psoriasis Patients With a Prior Suboptimal Response to IL-17 Inhibitor Therapy
Published: 2023-03-18 (Crawled : 16:20) - prnewswire.com
ABBV | $163.45 1.1% 1.3M
|
Health Technology
| Email alert
Add to watchlist
il-17 skyrizi abbvie psoriasis response therapy results study
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Moderate to Severe Active Crohn's Disease
Published: 2022-11-23 (Crawled : 08:00) - prnewswire.com
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: 0.1%
H: 0.62%
C: -0.35%
skyrizi treatment disease active approval
AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq
Published: 2022-10-31 (Crawled : 16:00) - biospace.com/
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: -1.65%
H: 1.11%
C: 0.85%
skyrizi rinvoq
AbbVie Drops Autoimmune Program, Prioritizes Skyrizi and Rinvoq
Published: 2022-10-31 (Crawled : 14:00) - biospace.com/
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: -1.65%
H: 1.11%
C: 0.85%
skyrizi rinvoq
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Published: 2022-09-19 (Crawled : 08:00) - biospace.com/
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: -0.29%
H: 0.15%
C: -0.68%
skyrizi treatment disease chmp risankizumab positive
New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100
Published: 2022-09-10 (Crawled : 08:20) - prnewswire.com
ABBV | $163.45 1.1% 1.3M
|
Health Technology
| Email alert
Add to watchlist
skyrizi trials skin week 100 results
AbbVie's Skyrizi Becomes First FDA-Approved IL-23 Inhibitor for Crohn's Disease
Published: 2022-06-20 (Crawled : 12:20) - biospace.com/
ABBV | $163.45 1.1% 1.3M
|
Health Technology
| Email alert
Add to watchlist
il-23 skyrizi disease fda
SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults
Published: 2022-06-17 (Crawled : 12:20) - prnewswire.com
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
il-23 skyrizi fda disease active approval
The Lancet Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Risankizumab (SKYRIZI®) in Crohn's Disease
Published: 2022-05-27 (Crawled : 08:00) - prnewswire.com
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: -1.98%
H: 0.0%
C: 0.0%
skyrizi disease lancet risankizumab results phase 3
AbbVie Leans on Skyrizi, Rinvoq as Humira Rides off the Patent Cliff
Published: 2022-02-02 (Crawled : 21:00) - biospace.com/
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: 0.0%
patent skyrizi humira rinvoq
AbbVie’s SKYRIZI Offers New Option for Psoriatic Arthritis Sufferers
Published: 2022-01-24 (Crawled : 13:00) - biospace.com/
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: -0.33%
H: 0.32%
C: -0.5%
skyrizi
U.S. FDA Approves Second Indication for SKYRIZI® (risankizumab-rzaa) to Treat Adults with Active Psoriatic Arthritis
Published: 2022-01-21 (Crawled : 00:20) - biospace.com/
ABBV | $163.45 1.1% 1.3M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
skyrizi fda risankizumab
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.503 117.66% 21M
|
n/a
WISA 4 | $3.22 84.0% 56M
|
Electronic Technology
SXTC | $2.56 82.86% 11M
|
Health Technology
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
BTTR | $6.86 34.51% 5.2M
|
Manufacturing
SNGX | $0.51 32.09% 6.3M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.